Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07147101

Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment

Sponsor: Fudan University

View on ClinicalTrials.gov

Summary

To evaluate the efficacy and immune microenvironment changes in advanced hepatocellular carcinoma (HCC) patients receiving different first-line immunotherapy.

Official title: A Prospective, Non-interventional Study of Different First-line Immunotherapy in Advanced Hepatocellular Carcinoma Patients: Efficacy and Immune Microenvironment Dynamics

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

150

Start Date

2025-09-01

Completion Date

2028-09-01

Last Updated

2025-08-28

Healthy Volunteers

No

Interventions

DRUG

Sintilimab

Sintilimab will be administered by IV, 200 mg every 3 weeks

DRUG

Bevacizumab Biosimilar

Bevacizumab biosimilar will be administered by IV, 15 mg/kg every 3 weeks.

DRUG

Camrelizumab

Camrelizumab will be administered by IV, 200 mg every 2 weeks.

DRUG

Rivoceranib

Rivoceranib will be administered by oral 250 mg once daily.

DRUG

Nivolumab

Nivolumab will be administered by IV, 1 mg/kg every 3 weeks for up to four doses, followed by nivolumab 480 mg every 4 weeks

DRUG

Ipilimumab

Ipilimumab will be administered by IV, 3mg/kg every 3 weeks for up to four doses.

Locations (1)

Zhongshan Hospital, Fudan University

Shanghai, Shanghai Municipality, China